EZH2 and neoplasm: Additionally, we demonstrated that the anti-tumor effect of NK cells was significantly enhanced by EZH2 inhibitors, and when EZH2 small molecule inhibitors were combined with TIGIT-blocking monoclonal antibodies, the anti-tumor effect of NK cells was higher than that of cells receiving monotherapy, and the expression of NKP30, an NK immune molecule, was increased in primary cells.